2 High-Flying Growth Stocks With Massive Upside Potential
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
This is Huge News For Eli Lilly Investors
Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...
Weight-Loss Drugs Cut Drug and Alcohol Abuse, According to New Study
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...
ConsumerAffairs14h
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Ozempic Plaintiffs Push for Marketing Discovery After MDL Judge Imposes Limits
"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...
Health.com20h
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
STAT1d
Pharmalittle: We’re reading about using Lilly obesity drug to reduce sick days, Sanofi workers striking, and more
The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...
The Times of Northwest Indiana1d
Get Healthy: Drugs can jump-start weight loss, giving healthy eating, exercise habits time to work
“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...